# Study to Determine the Effects of Different Doses of Methotrexate (MTX) When Taken With Adalimumab in Subjects With Early Rheumatoid Arthritis (RA)

> **NCT01185301** · PHASE3 · COMPLETED · sponsor: **AbbVie (prior sponsor, Abbott)** · enrollment: 395 (actual)

## Conditions studied

- Early Rheumatoid Arthritis

## Interventions

- **BIOLOGICAL:** adalimumab
- **DRUG:** methotrexate

## Key facts

- **NCT ID:** NCT01185301
- **Lead sponsor:** AbbVie (prior sponsor, Abbott)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2012-09
- **Final completion:** 2012-09
- **Target enrollment:** 395 (ACTUAL)
- **Last updated:** 2013-11-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01185301

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01185301, "Study to Determine the Effects of Different Doses of Methotrexate (MTX) When Taken With Adalimumab in Subjects With Early Rheumatoid Arthritis (RA)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01185301. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*